Use of IABP to reduce mortality in extensive myocardial infarction with persistent ischemia.

Published: 02-07-2014 Last updated: 20-04-2024

To test if IABP therapy is useful in patients presenting with large acute myocardial infarction complicated by persistent ischemia (no-reflow).

Ethical reviewApproved WMOStatusRecruitment stoppedHealth condition typeMyocardial disorders

Study type Interventional

Summary

ID

NL-OMON42015

Source

ToetsingOnline

Brief title

IABP in extensive myocardial infarction

Condition

Myocardial disorders

Synonym

myocardial infarction; heart attack

Research involving

Human

Sponsors and support

Primary sponsor: Catharina-ziekenhuis

Source(s) of monetary or material Support: contracten met de industrie

(Maquet), Maquet

Intervention

Keyword: IABP, myocardial infarction, persistent ischemia

Outcome measures

Primary outcome

Mortality, development of heart failure within six months necessitating

hospital admission, and necessity for mechanical hemodynamic support

Secondary outcome

None.

Study description

Background summary

Patients presenting with large myocardial infarction and poor hemodynamic condition after successful stenting, have a poor prognosis with respect to outcome and development of heart failure in the future. In some of these patients, IABP is very effective, in others it is not.

Our hypothesis is that in patients in whom persistent ischemia is present (as represented by insufficient ST-segment resolution on the ECG) IABP will be beneficial; whereas in patients with pumpfailure without persistent ischemia, IABP is of little value.

Study objective

To test if IABP therapy is useful in patients presenting with large acute myocardial infarction complicated by persistent ischemia (no-reflow).

Study design

Open randomised pilot study in 100 patients fulfilling the inclusion criteria.

Intervention

Placement of an intra-aortic balloon pump (IABP)

Study burden and risks

2 - Use of IABP to reduce mortality in extensive myocardial infarction with persiste ... 12-05-2025

There is only a neglectable extra risk or burden for the patients compared with regular treatment.

Contacts

Public

Catharina-ziekenhuis

Michelangelolaan 2 Eindhoven 5623EJ NL

Scientific

Catharina-ziekenhuis

Michelangelolaan 2 Eindhoven 5623EJ NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

- Age 18 * 80 years old
- Acute ST-segment elevation myocardial infarction with summed ST-segment deviation *15 mm
- Insufficient ST-segment resolution (<50%) on the ECG made 10-30 minutes after the primary PCI in the catheterization laboratory.

Exclusion criteria

- Initial summed ST-segment deviation less than 15 mm
- ST-segment resolution *50% on the ECG performed in the catheterization laboratory
- Chest pain onset >8 hours before arrival
- Severe aortic valve stenosis/regurgitation
- Aortic abnormalities prohibitive for use of intra aortic balloon pump
- Full blown cardiogenic shock with immediate requirement of left ventricular assist device as judged necessary by the operator
- Inability to provide informed consent
- Pregnancy
- Inability to perform coronary angiography by the femoral approach

Study design

Design

Study type: Interventional

Intervention model: Parallel

Allocation: Randomized controlled trial

Masking: Open (masking not used)

Primary purpose: Treatment

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 25-08-2014

Enrollment: 100

Type: Actual

Medical products/devices used

Generic name: Intra Aortic Balloon pump (IABP)

Registration: Yes - CE intended use

Ethics review

Approved WMO

Date: 02-07-2014

Application type: First submission

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 03-11-2014

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 11-05-2015

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 10-12-2015

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

ClinicalTrials.gov NCT02125526 CCMO NL48245.060.14